Sobetirome in the treatment of myelination diseases
Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.
1. A method of treating a subject having acute hypoxemic respiratory failure, comprising administering to the subject a therapeutically effective amount of sobetirome or a pharmaceutically acceptable salt thereof.
2. A method of treating a subject having a disease or disorder selected from acute disseminated encephalomyelitis (ADEM), progressive multifocal leukoencephalopathy (PML), tropical spastic paraparesis (TSP), chronic inflammatory demyelinating polyneuropathy, transverse myelitis, and Guillain-Barre syndrome, comprising administering to the subject a therapeutically effective amount of sobetirome or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 wherein the disease or disorder is acute disseminated encephalomyelitis (ADEM).
4. The method of claim 2 wherein the disease or disorder is progressive multifocal leukoencephalopathy (PML).
5. The method of claim 2 wherein the disease or disorder is tropical spastic paraparesis (TSP).
6. The method of claim 2 wherein the disease or disorder is chronic inflammatory demyelinating polyneuropathy.
7. The method of claim 2 wherein the disease or disorder is transverse myelitis.
8. The method of claim 2 wherein the disease or disorder is Guillain-Barre syndrome.